article thumbnail

Leveraging innate cell engagers for lymphoma treatment

European Pharmaceutical Review

Following their introduction, these therapies have moved to early lines of treatment, but unfortunately, a significant number of patients are not cured with these approaches. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

article thumbnail

It’s Time We Got the Most Out of Medical Affairs Data

PM360

Field Medical Affairs is an essential bridge between pharmaceutical clinical development and commercial delivery. Historically, the industry has left MSL-HCP interactions to exist on their own, focusing on objective metrics and key performance indicators (KPIs) to inform Medical Affairs impact.

Medical 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Currency of Information

PM360

Medical science Liaisons know that change is coming; How are they cashing in? Medical science liaisons (MSLs) within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering.

article thumbnail

Recurrent drug shortages signal onerous outlook for cardiovascular care

Pharmaceutical Technology

According to the agency, shortages of both drugs are expected to last until 2024, as a result of growing demand. These] are life-saving medications. And patients can die when we do not have these readily available,” he says. Here, the long-term shortages can be attributed to two factors, says Page.

Medicine 111
article thumbnail

8 Tactics to Increase HCP Engagement in 2024

PM360

A significant battle for the hearts and minds of healthcare professionals (HCPs) will play out in social media during 2024. Mobilize MSLs Peer-to-Peer demand is driving reliance on social media to connect HCPs with others serving similar patient populations or confronting similar treatment considerations.

Media 122